These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Camidge DR; Dziadziuszko R; Hirsch FR Clin Lung Cancer; 2009 Jul; 10(4):262-72. PubMed ID: 19632946 [TBL] [Abstract][Full Text] [Related]
3. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Reeve JG; Morgan J; Schwander J; Bleehen NM Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401 [TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183 [TBL] [Abstract][Full Text] [Related]
5. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049 [TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. Nakanishi Y; Mulshine JL; Kasprzyk PG; Natale RB; Maneckjee R; Avis I; Treston AM; Gazdar AF; Minna JD; Cuttitta F J Clin Invest; 1988 Jul; 82(1):354-9. PubMed ID: 2839551 [TBL] [Abstract][Full Text] [Related]
10. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Sacco A; Morcavallo A; Pandini G; Vigneri R; Belfiore A Endocrinology; 2009 Aug; 150(8):3594-602. PubMed ID: 19443570 [TBL] [Abstract][Full Text] [Related]
11. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208 [TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Bostedt KT; Schmid C; Ghirlanda-Keller C; Olie R; Winterhalter KH; Zapf J Exp Cell Res; 2001 Dec; 271(2):368-77. PubMed ID: 11716549 [TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Shen MR; Hsu YM; Hsu KF; Chen YF; Tang MJ; Chou CY Carcinogenesis; 2006 May; 27(5):962-71. PubMed ID: 16400188 [TBL] [Abstract][Full Text] [Related]
14. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy. Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933 [TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner. Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909 [TBL] [Abstract][Full Text] [Related]
16. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Scagliotti GV; Novello S Cancer Treat Rev; 2012 Jun; 38(4):292-302. PubMed ID: 21907495 [TBL] [Abstract][Full Text] [Related]
17. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546 [TBL] [Abstract][Full Text] [Related]
18. Effects of insulin, insulin-like growth factor-I and -II on proliferation and intracellular signaling in endometrial carcinoma cells with different expression levels of insulin receptor isoform A. Wang CF; Zhang G; Zhao LJ; Li XP; Qi WJ; Wang JL; Wei LH Chin Med J (Engl); 2013; 126(8):1560-6. PubMed ID: 23595395 [TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799 [TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Põld M; Krysan K; Põld A; Dohadwala M; Heuze-Vourc'h N; Mao JT; Riedl KL; Sharma S; Dubinett SM Cancer Res; 2004 Sep; 64(18):6549-55. PubMed ID: 15374967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]